Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid.
Adult
Aged
Aged, 80 and over
Autoantibodies
/ blood
Autoantigens
/ genetics
Biological Assay
Biomarkers
/ blood
Case-Control Studies
Cell Adhesion Molecules
/ genetics
Female
Fluorescent Antibody Technique, Indirect
Germany
HEK293 Cells
Humans
Japan
Keratinocytes
/ immunology
Male
Middle Aged
Netherlands
Pemphigoid, Benign Mucous Membrane
/ blood
Predictive Value of Tests
Reproducibility of Results
Kalinin
autoantibody
biochip
blistering
cancer
footprint
laminin 332
malignancy
mucous membrane pemphigoid
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2021
accepted:
26
10
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
19
2
2022
Statut:
epublish
Résumé
Anti-laminin 332 mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by predominant mucosal lesions and autoantibodies against laminin 332. The exact diagnosis of anti-laminin 332 MMP is important since nearly 30% of patients develop solid cancers. This study compared two independently developed diagnostic indirect immunofluorescence (IF) tests based on recombinant laminin 332 expressed in HEK239 cells (biochip mosaic assay) and the migration trails of cultured keratinocytes rich in laminin 332 (footprint assay). The sera of 54 anti-laminin 332 MMP, 35 non-anti-laminin 332 MMP, and 30 pemphigus vulgaris patients as well as 20 healthy blood donors were analyzed blindly and independently. Fifty-two of 54 and 54/54 anti-laminin 332 MMP sera were positive in the biochip mosaic and the footprint assay, respectively. In the 35 non-anti-laminin 332 MMP sera, 3 were positive in both tests and 4 others showed weak reactivity in the footprint assay. In conclusion, both assays are easy to perform, highly sensitive, and specific, which will further facilitate the diagnosis of anti-laminin 332 MMP.
Identifiants
pubmed: 34899726
doi: 10.3389/fimmu.2021.773720
pmc: PMC8657402
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Biomarkers
0
Cell Adhesion Molecules
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
773720Informations de copyright
Copyright © 2021 Goletz, Giurdanella, Holtsche, Nijenhuis, Horvath, Diercks, Zillikens, Hashimoto, Schmidt and Pas.
Déclaration de conflit d'intérêts
DZ and ES have obtained grants from Euroimmun, Lübeck, for research and development projects. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Dermatol. 1998 Mar;8(2):83-5
pubmed: 9649654
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):1926-1948
pubmed: 34309078
Br J Dermatol. 2003 May;148(5):939-44
pubmed: 12786824
J Dermatol Sci. 2003 Nov;33(2):113-9
pubmed: 14581137
Clin Immunol. 2001 Oct;101(1):100-5
pubmed: 11580232
Br J Dermatol. 2006 Jan;154(1):90-8
pubmed: 16403100
Orphanet J Rare Dis. 2018 Jul 6;13(1):111
pubmed: 29980216
J Dtsch Dermatol Ges. 2018 Sep;16(9):1077-1091
pubmed: 30179336
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Apr;117(4):483-96
pubmed: 24556492
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1750-1764
pubmed: 34245180
Arch Dermatol. 2002 Mar;138(3):370-9
pubmed: 11902988
J Dermatol. 2004 Jan;31(1):10-5
pubmed: 14739497
Br J Dermatol. 2010 Apr;162(4):743-50
pubmed: 19886889
Int J Dermatol. 2018 Jan;57(1):86-88
pubmed: 29130487
Br J Dermatol. 2001 Nov;145(5):778-83
pubmed: 11736901
Br J Dermatol. 1998 Nov;139(5):791-7
pubmed: 9892943
JAMA Dermatol. 2013 May;149(5):533-40
pubmed: 23426192
Acta Derm Venereol. 2016 Aug 23;96(6):768-73
pubmed: 26631393
Br J Dermatol. 2020 Feb;182(2):270-271
pubmed: 31448410
J Clin Invest. 1992 Oct;90(4):1628-33
pubmed: 1401088
Dtsch Arztebl Int. 2011 Jun;108(23):399-405, I-III
pubmed: 21712975
Br J Dermatol. 2020 Feb;182(2):373-381
pubmed: 31090065
Clin Exp Dermatol. 2009 Dec;34(8):e992-4
pubmed: 19832858
Exp Dermatol. 2017 Dec;26(12):1154-1162
pubmed: 28887824
J Dtsch Dermatol Ges. 2015 Jul;13(7):713-27
pubmed: 26110729
Br J Dermatol. 2011 Jan;164(1):76-82
pubmed: 20854435
Lancet. 2001 Jun 9;357(9271):1850-1
pubmed: 11410196
J Am Acad Dermatol. 2008 Jun;58(6):951-8
pubmed: 18396347
J Am Acad Dermatol. 2004 Dec;51(6):886-92
pubmed: 15583578
Br J Dermatol. 2011 Oct;165(4):815-22
pubmed: 21692774
Br J Dermatol. 2019 Jan;180(1):149-156
pubmed: 30216412
Arch Dermatol. 1999 Sep;135(9):1091-8
pubmed: 10490114